ASTRAZEN2023-10-012023-12-31 ASTRAZEN2023-10-012023-12-31 ASTRAZEN2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member ASTRAZEN2023-10-012023-12-31in-bse-fin:OneOperatingExpenses02Member ASTRAZEN2023-10-012023-12-31in-bse-fin:OneOperatingExpenses03Member ASTRAZEN2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member ASTRAZEN2023-10-012023-12-31in-bse-fin:FourOperatingExpenses02Member ASTRAZEN2023-10-012023-12-31in-bse-fin:FourOperatingExpenses03Member ASTRAZEN2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 506820 ASTRAZEN NA AstraZeneca Pharma India Limited Equity 2023-04-01 2024-03-31 2024-02-08 2024-01-25 INR Lakhs Third quarter 14:45:00 17:55:00 2024-02-08 2024-02-08 Not applicable Single segment Healthcare 2023-10-01 2023-12-31 Unaudited Standalone 3057890000.00 96600000.00 3154489000.00 375188000.00 1815337000.00 -707611000.00 632336000.00 6127000.00 37047000.00 792072000.00 2950496000.00 203993000.00 0.00 203993000.00 46534000.00 -550000.00 45984000.00 0.00 158010000.00 0.00 0.00 0.00 0.00 158010000.00 531000.00 158540000.00 0.00 0.00 50000000.00 2 6.32 6.32 0.00 0.00 6.32 6.32 Notes: 1. The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. 2. The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided. 3. Consequent to Company's announcement to Stock exchange on 16 November 2023 on its intention to exit the manufacturing site in Bangalore in due course, the Company has started its search for a buyer who can also act as a Contract Manufacturing Organisation. 4. Exceptional items for the quarter and year ended 31 March 2023 consists of seperation cost amounting to Rs.1,910.32 lakhs and Voluntary Retirement Scheme expenses amounting to Rs.2,112.59 lakhs. 5. Exceptional items for the quarter ended 30 September 2023 consists of amount pertaining to certain previously disputed disclosed Transfer Pricing matters amounting to Rs.1642.63 lakhs. 6. This statement of financial results was reviewed and recommended by the Audit Commiltee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 8 February 2024. The Statutory auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 31 December 2023. By Order of the Board of Directors For AstraZeneca Pharma India Limited Place: Bengaluru Sanjeev Kumar Panchal Date: 8 February 2024 Managing Director Single segment 2023-04-01 2023-12-31 Unaudited Standalone 9123274000.00 261365000.00 9384639000.00 953984000.00 4243276000.00 -1387191000.00 1834744000.00 12663000.00 111764000.00 2127847000.00 7897087000.00 1487552000.00 164263000.00 1651815000.00 434143000.00 -2642000.00 431501000.00 0.00 1220314000.00 0.00 0.00 0.00 0.00 1220314000.00 7955000.00 1228269000.00 0.00 0.00 50000000.00 2 48.81 48.81 0.00 0.00 48.81 48.81 Allowance for expected credit loss (net) -309000.00 Other Expenses 508852000.00 Selling, marketing and distribution expenses 283529000.00 Allowance for expected credit loss (net) 12595000.00 Other Expenses 1466626000.00 Selling, marketing and distribution expenses 648627000.00 709000.00 10630000.00 178000.00 2675000.00 0.00 0.00